<DOC>
	<DOCNO>NCT00042796</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop cancer cell divide stop grow die . This phase I trial study side effect best dose decitabine treat child relapse refractory acute myeloid leukemia acute lymphoblastic leukemia</brief_summary>
	<brief_title>Decitabine Treating Children With Relapsed Refractory Acute Myeloid Leukemia Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose decitabine associate consistent evidence deoxyribonucleic acid ( DNA ) demethylation child relapse refractory acute myeloid leukemia acute lymphoblastic leukemia . II . Determine dose-limiting toxicity , pharmacokinetics , antitumor activity drug patient . III . Determine biologic correlate decitabine-induced DNA demethylation characterizing , treatment , global specific DNA methylation status ( use methylation microarrays ) hemoglobin F level patient . IV . Determine biologic correlate decitabine-induced DNA demethylation characterizing , treatment , global change gene expression profile use cDNA microarrays drug sensitivity blast cell MTT assay patient . V. Determine biologic correlate decitabine-induced DNA demethylation characterizing , treatment , deletion single nucleotide polymorphisms genomic DNA deoxycytidine kinase cytidine deaminase gene patient . VI . Determine biologic correlate decitabine-induced DNA demethylation characterizing , treatment , acetylation methylation histone H3 H4 helicase protein expression patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord disease type ( acute myeloid leukemia v acute lymphoblastic leukemia ) . Patients receive decitabine IV 1 hour day 1-5 8-12 . Treatment repeat every 4-6 week minimum 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos decitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 15-21 patient accrue study within 7.5-21 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histologically confirm acute myeloid leukemia ( AML ) acute lymphoblastic leukemia consider refractory conventional therapy conventional therapy exists For patient AML : M3 marrow M2 marrow least 15 % blast Secondary AML allow CNS involvement allow Performance status Karnofsky 50100 % ( age 17 21 ) Performance status Lansky 50100 % ( age 16 ) At least 8 week See Chemotherapy WBC great 30,000/mm^3 Patients granulocytopenia , anemia , and/or thrombocytopenia eligible evaluable hematological toxicity Bilirubin great 1.5 time normal ALT great 5 time normal Albumin least 2 g/dL Creatinine great 1.5 time normal Creatinine clearance radioisotope glomerular filtration rate least low limit normal Shortening fraction least 27 % echocardiogram Ejection fraction least 50 % MUGA scan No evidence dyspnea rest No exercise intolerance Oxygen saturation great 94 % pulse oximetry Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Concurrent seizure disorder allow well control anticonvulsant No grade 2 great CNS toxicity No uncontrolled infection ( i.e. , infection associate fever , dissemination , hemodynamic instability [ require pressor support ] , progression therapy ) No active graftversushost disease ( GVHD ) GVHD well control cyclosporine allow Recovered prior immunotherapy At least 1 week since prior biologic agent At least 6 month since prior allogeneic bone marrow transplantation ( BMT ) At least 3 month since prior autologous BMT No concurrent sargramostim ( GMCSF ) No concurrent prophylactic filgrastim ( GCSF ) first course therapy Recovered prior chemotherapy At least 4 week since prior cytarabine At least 24 hour since prior cytoreductive therapy hydroxyurea ( 2030 mg/kg/day 7 day ) low WBC great 30,000/mm^3 No concurrent intrathecal therapy first course decitabine Recovered prior radiotherapy At least 2 week since prior local palliative radiotherapy ( small port ) At least 6 week since prior cranial craniospinal radiotherapy No concurrent medication induce cytidine deaminase deoxycytidine kinase ( e.g. , cytarabine ) No concurrent medication mask poor deteriorate organ function No concurrent CNS prophylaxis first course decitabine Concurrent anticonvulsant know interaction decitabine allow Concurrent antibacterial antifungal therapy control infection allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>